Results 301 to 310 of about 337,050 (372)

Dr. Hans Kohn and the political takeover of the Berlin Medical Society by the National Socialist regime in 1933

The Anatomical Record, EarlyView.
Abstract To solidify their power over society, totalitarian regimes will usually eliminate any dissent, any perceived threats early on. These threats include not only political enemies but also educated and independent segments of society, such as professional associations.
Michael Hortsch
wiley   +1 more source

Integrating Radiologic and Clinical Features to Predict VSX1 Expression in Clear Cell Renal Cell Carcinoma. [PDF]

Curr Oncol
Greco F, Panunzio A, Sergi D, Cataldo M, Bernetti C, Tafuri A, Beomonte Zobel B, Mallio CA.   +7 more
europepmc   +1 more source

Histone Methyltransferase Gene SETD2 Is a Novel Tumor Suppressor Gene in Clear Cell Renal Cell Carcinoma

, 2010
Gerben Duns, Anke van den Berg, Inge van Duivenbode, Jan Osinga, Harry Hollema, Robert M.W. Hofstra, Klaas Kok   +6 more
openalex   +1 more source

The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma

Oncogene, 2018
H. Miess, Beatrice Dankworth, A. Gouw, M. Rosenfeldt, W. Schmitz, M. Jiang, Becky Saunders, M. Howell, J. Downward, D. Felsher, B. Peck, A. Schulze   +11 more
semanticscholar   +1 more source

Approaches to repurposing reverse transcriptase antivirals in cancer

British Journal of Clinical Pharmacology, EarlyView.
This review highlights the role of reverse transcriptase (RT) inhibition in cellular regulation associated with non‐terminal repeat retrotransposons and endogenous retroviruses. Based on their pleiotropic characteristics, RT inhibitors (RTIs) are discussed as potential anticancer agents.
Richard Head, Saiful Islam, Jennifer H. Martin   +2 more
wiley   +1 more source

GPD1L as a potential biomarker associated with Treg cell infiltration and lipid metabolism in clear cell renal cell carcinoma. [PDF]

J Transl Med
Yang M, Pang D, Gong C, Song K, Ma H, Yang Y, Guo S, Wang L.   +7 more
europepmc   +1 more source

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Casdatifan is an orally bioavailable small‐molecule hypoxia‐inducible factor‐2α (HIF‐2α) inhibitor currently in development for treating patients with clear cell renal cell carcinomas. The aim of this study was to characterize the pharmacokinetics (PK), pharmacodynamics and safety of casdatifan in healthy participants.
Mohammad Ghasemi, Ji Yun Kim, Lisa Seitz, Lixia Jin, Paul G. Foster, Kai H. Liao, Tzuling Cheng, Elaine Paterson, Maria Velinova, Nicole Rivera Rosario, Reza Khosravan, Balaji Agoram   +11 more
wiley   +1 more source

KCNJ2 Facilitates Clear Cell Renal Cell Carcinoma Progression and Glucose Metabolism. [PDF]

Int J Genomics
Zhao Q, Wei Z, Yang G, Wei L, Chen H, Cui Z, Liao N, Qin M, Cheng J.   +8 more
europepmc   +1 more source

Engineering antibodies with cancer‐associated binding sites

BMEMat, EarlyView.
This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian, Yumeng Pan, Yingchun Zhang, Fangling Wang, Zejun Wang   +4 more
wiley   +1 more source

The impact of radiotherapy on the prognosis of metastatic clear cell renal cell carcinoma after surgery. [PDF]

Sci Rep
Li X, Tan Z, Zhu Y, Zhai Y, Chen C, Wang D, Wang M, Xing N, Yang F, Ye X.   +9 more
europepmc   +1 more source